Related Experiment Video
Updated: Feb 1, 2026

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
Amyloid Cardiomyopathy in the Emergency Department
Mauricio Baca1, Mark Newberry2
1Department of Emergency Medicine, Mount Sinai Medical Center, Miami Beach, Florida.
Insights
Cardiac amyloidosis, a cause of restrictive cardiomyopathy, presents unique challenges in the emergency department. Prompt identification is crucial for appropriate heart failure management, avoiding certain medications.
Area of Science:
- Cardiology
- Internal Medicine
- Emergency Medicine
Background:
- Cardiac amyloidosis is an underdiagnosed cause of restrictive cardiomyopathy.
- Amyloid protein infiltration of the myocardium leads to heart failure.
Observation:
- An 83-year-old woman presented with dyspnea and swelling, exhibiting signs of heart failure.
- Echocardiography revealed severe concentric ventricular hypertrophy with a "sparkling" myocardium.
- Nuclear medicine pyrophosphate study suggested cardiac amyloidosis.
Findings:
- Emergency physicians often manage heart failure with standard treatments.
- Amyloid cardiomyopathy requires specific management, including loop diuretics.
- Certain heart failure medications (beta-blockers, ACE inhibitors, calcium channel blockers, digoxin) are contraindicated.
Implications:
- Early recognition of cardiac amyloidosis in the ED is vital for patient outcomes.
- Avoiding specific medications prevents adverse events in amyloid cardiomyopathy.
- Understanding unique hemodynamic profiles guides emergency treatment strategies.
Background:
Cardiac amyloidosis is an underdiagnosed cause of restrictive cardiomyopathy resulting from the infiltration of the myocardium by amyloid proteins.
Case Report:
We report the case of an 83-year-old woman who presented with increasing dyspnea and lower-extremity swelling. She reported a medical history of unspecified heart failure. Evaluation in the Emergency Department (ED) revealed evidence of heart failure on physical examination, low-voltage electrocardiogram, chest x-ray study with mild pulmonary edema, and laboratory evaluation with elevated brain natriuretic peptide and troponin. Bedside cardiac ultrasound illustrated severe concentric ventricular hypertrophy and interventricular septal wall thickening with "sparkling" hyperechoic appearance of the myocardium, mildly reduced left ventricular ejection fraction, and small pericardial effusion. Inpatient comprehensive echocardiogram and follow-up nuclear medicine cardiac amyloid pyrophosphate study were suggestive of cardiac amyloidosis. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Emergency physicians commonly treat acute on chronic systolic heart failure with diuresis and reductions in preload and afterload with nitrates. Identifying amyloid cardiomyopathy in the ED is of clinical significance because treatment should include loop diuretics but should avoid β-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, and digoxin. Atrioventricular nodal blocking agents may have detrimental effects in cardiac amyloidosis because the cardiac output in this patient population is dependent on heart rate due to a significantly reduced stroke volume from the concentric hypertrophy minimizing diastolic filling. Also, caution should be taken when initiating nitrates in amyloid cardiomyopathy because further reducing preload in an already preload-depleted state can result in hypotension.
More Related Videos
07:52Expired CO2 Measurement in Intubated or Spontaneously Breathing Patients from the Emergency Department
Published on: January 29, 2011
09:52Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
Published on: January 15, 2017
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Emerging Adulthood